GleamWall
中文EN

OBIO Orchestra BioMed Holdings, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1814114 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY1,007.4%
TTM net income YoY24.2%
TTM EPS YoY58.3%
Revenue 3-yr CAGR105.4%
Net income 3-yr CAGR—

Margins

Gross margin99.6%
Operating margin-195.4%
Net margin-182.5%
FCF margin-205.7%
EBITDA margin-194.2%

Returns

ROE-221.1%
ROA-53.6%
ROIC (approx.)—
Asset turnover0.29x

Leverage & solvency

Liabilities / assets82.6%
Debt / equity0.00x
Current ratio7.25x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.11x
Accruals ratio6.0%
Payout ratio—
Capex / revenue2.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$91,000$88,000$110,000$30.92M$861,000$836,000$868,000$253,000
Cost of revenue$28,000$25,000$32,000$51,000$49,000$46,000$44,000$58,000
Gross profit$63,000$63,000$78,000$30.87M$812,000$790,000$824,000$195,000
R&D expense$17.73M$16.59M$15.78M$16.82M$14.03M$13.85M$13.48M$10.97M
SG&A expense$5.62M$5.83M$6.37M$7.29M$7.10M$6.26M$6.26M$5.90M
Operating income-$23.30M-$22.36M-$22.08M$6.75M-$20.31M-$19.33M-$18.92M-$16.68M
Interest expense———————$297,000
Net income-$18.75M-$23.75M-$20.69M$6.25M-$20.83M-$19.36M-$18.75M-$16.16M
EBITDA-$23.20M-$22.26M-$21.99M$6.84M-$20.23M-$19.25M-$18.84M-$16.59M
EPS (basic)-0.30-0.38-0.33—-0.40-0.50-0.49—
EPS (diluted)-0.30-0.38-0.33—-0.40-0.50-0.49—
Weighted avg. shares (diluted)64.62M63.81M62.72M—52.19M38.39M38.24M—
Balance sheet
Cash & equivalents$27.76M$20.47M$28.37M$34.69M$42.01M$18.75M$18.35M$22.26M
Short-term investments$74.15M$89.49M$66.03M$71.82M$53.81M$15.18M$31.54M$44.55M
Receivables$56,000$51,000$84,000$95,000$52,000$83,000$89,000$92,000
Inventory$221,000$250,000$277,000$310,000$365,000$185,000$135,000$173,000
Current assets$103.17M$111.24M$96.21M$107.91M$97.77M$35.88M$51.90M$69.17M
PP&E, net$2.28M$2.04M$1.85M$1.72M$1.59M$1.37M$1.41M$1.38M
Total assets$107.74M$115.70M$100.66M$114.86M$104.81M$42.83M$59.05M$76.17M
Current liabilities$14.23M$13.47M$13.69M$16.74M$20.66M$17.06M$15.49M$16.21M
Long-term debt——$15.00M$15.00M$15.00M$15.00M$15.00M$15.00M
Total debt——$15.00M$15.00M$15.00M$15.00M$15.00M$15.00M
Total liabilities$88.99M$86.28M$49.69M$51.48M$61.07M$42.53M$42.19M$43.22M
Shareholders' equity$7.78M$19.32M$41.19M$53.57M$43.74M$295,000$16.86M$32.96M
Net debt——-$13.37M-$19.69M-$27.01M-$3.75M-$3.35M-$7.26M
Shares outstanding61.45M60.11M58.63M57.03M56.46M38.64M38.31M38.19M
Cash flow statement
Operating cash flow-$19.54M-$19.33M-$22.17M-$2.27M-$14.55M-$15.53M-$16.62M-$13.54M
Capital expenditure$398,000$254,000$184,000$33,000$310,000$34,000$112,000$106,000
Free cash flow-$19.94M-$19.59M-$22.35M-$2.30M-$14.86M-$15.56M-$16.73M-$13.64M
Investing cash flow$20.96M-$23.31M$10.32M-$17.71M-$38.58M$16.36M$13.00M-$3.75M
Financing cash flow$5.86M$34.75M$5.53M$12.66M$76.40M-$428,000-$296,000$13.95M
Depreciation & amortization$101,000$96,000$90,000$82,000$81,000$81,000$83,000$84,000
Stock-based compensation$2.29M$2.50M$2.85M$2.75M$3.01M$3.25M$2.96M$2.90M

Free plan shows the latest 8 periods; Pro shows all 24 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.